Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer
Christina Hartl(Io Therapeutics (United States)), Michael S. Goldberg(Einstein Medical Center Philadelphia)
Cited by 36
Related Papers
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
|Nature Communications|2017|440
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
|Nature Cancer|2020|271